{"meta":{"query_hash":"59bc5d409406","filters":{"venue":"PharmaDeals Review"},"cohort_total":12,"direct_labels_cover":0,"predictions_cover":12,"exported":12,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/59bc5d409406","api":"https://metacan.xera.ac/api/v1/cohort?venue=PharmaDeals+Review"},"results":[{"id":"W128615782","doi":"10.3833/pdr.v2012i3.1692","title":"Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Dupuytren's Contracture and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Political science; Medicine; Management; Family medicine; Economics","score_opus":0.06126565779868655,"score_gpt":0.39629554123680627,"score_spread":0.33502988343811974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W128615782","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059639835,0.10577499,0.00141675,0.05407439,0.003588605,0.0003424591,0.0009113024,0.00035395415,0.8275736],"genre_scores_gemma":[0.042939838,0.040308718,0.0018792168,0.012832224,0.0012189839,0.00017009405,0.00066025567,0.000077578516,0.8999131],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985885,0.00013780268,0.000054233104,0.00017585323,0.00078628317,0.00025723383],"domain_scores_gemma":[0.99777764,0.00037240528,0.00018473413,0.000105321196,0.0009298237,0.00063011906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002621183,0.00053048827,0.00053321413,0.0010376761,0.0019947202,0.0018805938,0.0006451095,0.003560573,0.09390334],"category_scores_gemma":[0.0033698126,0.00021993325,0.0004972218,0.0009458678,0.00082910474,0.0015128253,0.0011064579,0.0020522254,0.012003509],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043417548,0.00013583494,0.001048402,0.0008429805,0.000035440746,0.0013489309,0.0004143852,0.00017974667,0.0057224003,0.076522306,0.51148504,0.4018304],"study_design_scores_gemma":[0.000025970176,0.000046198315,0.00061327533,0.00013847621,0.000007858091,0.0003028322,0.000033176377,0.000029565876,0.00031339563,0.0002203023,0.9982645,0.0000045342117],"about_ca_topic_score_codex":0.16627753,"about_ca_topic_score_gemma":0.23882756,"teacher_disagreement_score":0.8337225,"about_ca_system_score_codex":0.0052875127,"about_ca_system_score_gemma":0.018319473,"threshold_uncertainty_score":0.3306194},"labels":[],"label_agreement":null},{"id":"W131397720","doi":"10.3833/pdr.v2011i5.1473","title":"Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Business","score_opus":0.2517164448078097,"score_gpt":0.43659777920550064,"score_spread":0.18488133439769094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W131397720","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009744058,0.07652071,0.0019792838,0.018431956,0.0024741308,0.00029793623,0.00085079035,0.0003910136,0.8893101],"genre_scores_gemma":[0.09663953,0.0444077,0.005419466,0.0071189553,0.0017632586,0.00022580422,0.0016795945,0.00018132928,0.8425643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988667,0.00014409405,0.000060694652,0.00014118689,0.00064649404,0.00014088693],"domain_scores_gemma":[0.99856085,0.00035189246,0.00018018353,0.00008863005,0.0004819341,0.00033643813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016540319,0.0004662272,0.0003862891,0.00079365954,0.00083060766,0.0013283722,0.0003869409,0.0021612286,0.09689659],"category_scores_gemma":[0.001942438,0.0002218568,0.00049562287,0.00057449285,0.00060517556,0.0014618252,0.00080803054,0.0013846846,0.02050132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007164581,0.00026575042,0.0010393066,0.0010850701,0.00002843492,0.0014259509,0.00031977423,0.000111742585,0.03154284,0.028737761,0.29620394,0.6385229],"study_design_scores_gemma":[0.000062439736,0.00020470915,0.0011621474,0.00016385011,0.000010840728,0.000837556,0.000044551674,0.00004723129,0.003163948,0.00042298588,0.9938725,0.0000072358134],"about_ca_topic_score_codex":0.004392122,"about_ca_topic_score_gemma":0.007614599,"teacher_disagreement_score":0.09689659,"about_ca_system_score_codex":0.0012556321,"about_ca_system_score_gemma":0.0037513396,"threshold_uncertainty_score":0.3241514},"labels":[],"label_agreement":null},{"id":"W150401912","doi":"10.3833/pdr.v2011i6.1485","title":"Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmacology and Obesity Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Milestone; Type 2 diabetes; Payment; Obesity; Quarter (Canadian coin); Business; Diabetes mellitus; Internal medicine; Finance; Endocrinology; Geography","score_opus":0.08240199183654418,"score_gpt":0.3650932836274937,"score_spread":0.28269129179094954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W150401912","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0151075795,0.24371044,0.018297164,0.015724832,0.006165507,0.0024226008,0.00841501,0.004159301,0.68599755],"genre_scores_gemma":[0.04371347,0.07704128,0.01714911,0.0026131659,0.00072786433,0.0010628573,0.0063286545,0.0003896276,0.85097396],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992042,0.00010925739,0.000049609265,0.0001372257,0.0004027111,0.00009706282],"domain_scores_gemma":[0.99917394,0.00022906742,0.0000900053,0.000068210094,0.0002447188,0.00019393722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015817921,0.0015400214,0.0009635446,0.0014299578,0.00049318926,0.0010828705,0.000734316,0.0019177116,0.13348551],"category_scores_gemma":[0.002202543,0.0006473921,0.00077538507,0.0009025202,0.0006898682,0.0012099423,0.0008683789,0.0022724485,0.06861438],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001295465,0.00029898647,0.00048049394,0.0035192939,0.00010567929,0.0013092686,0.00017832233,0.00025220634,0.075112134,0.011265784,0.26418823,0.6419942],"study_design_scores_gemma":[0.0006006438,0.0006570631,0.0015605552,0.0005742679,0.000092607916,0.0015089941,0.0000463114,0.00025771518,0.007291645,0.001214279,0.9861712,0.000024780717],"about_ca_topic_score_codex":0.004254906,"about_ca_topic_score_gemma":0.0065589375,"teacher_disagreement_score":0.13348551,"about_ca_system_score_codex":0.0005524302,"about_ca_system_score_gemma":0.002675557,"threshold_uncertainty_score":0.44655353},"labels":[],"label_agreement":null},{"id":"W1578951455","doi":"10.3833/pdr.v2013i4.1921","title":"Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alliance; Product (mathematics); Disease; Political science; Business; Medicine; Internal medicine","score_opus":0.13993692469553828,"score_gpt":0.4159867448974022,"score_spread":0.27604982020186397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1578951455","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024731526,0.29998735,0.00467266,0.11042137,0.023091547,0.0023930315,0.008060788,0.0017446614,0.5248971],"genre_scores_gemma":[0.067607306,0.09946405,0.0074003064,0.019015688,0.0033708832,0.0010789755,0.008507386,0.0003441818,0.7932113],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99883956,0.00016654952,0.00006041754,0.00017442244,0.00047527152,0.00028386904],"domain_scores_gemma":[0.9977841,0.0002575922,0.0001774662,0.000081404054,0.00070043205,0.0009990651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00275203,0.00091592956,0.0006559682,0.0012543269,0.0007452261,0.0020974772,0.00094941567,0.0037278929,0.07126162],"category_scores_gemma":[0.0023368627,0.00027003675,0.0007636113,0.00064574217,0.0005622657,0.0018131257,0.0014835487,0.0033986678,0.031587277],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024442128,0.00086466986,0.0010628412,0.0013458962,0.0000775047,0.0012028939,0.00016296787,0.00015410886,0.005585977,0.013210156,0.5802145,0.39367428],"study_design_scores_gemma":[0.00060430047,0.0005216733,0.0013071793,0.0002848134,0.000044389875,0.0005823004,0.000049280025,0.00006250526,0.0011646585,0.00080055697,0.99456835,0.000009970758],"about_ca_topic_score_codex":0.002843133,"about_ca_topic_score_gemma":0.00612886,"teacher_disagreement_score":0.07126162,"about_ca_system_score_codex":0.0018767751,"about_ca_system_score_gemma":0.0075007593,"threshold_uncertainty_score":0.23839384},"labels":[],"label_agreement":null},{"id":"W202721108","doi":"10.3833/pdr.v2011i8.1518","title":"Bayer Licenses Regional Rights to Trius Therapeutics’ Phase III Antibiotic for Serious Gram-Positive Infections","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"China; Latin Americans; Medicine; International trade; Political science; Business; Law","score_opus":0.20075728967151268,"score_gpt":0.38651749375098643,"score_spread":0.18576020407947375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W202721108","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012193459,0.09399467,0.006678995,0.0379365,0.0030474435,0.00066434557,0.008750983,0.002432851,0.83430076],"genre_scores_gemma":[0.14741948,0.049211062,0.006931272,0.012736825,0.0025224327,0.00047062212,0.012275678,0.0004918466,0.76794076],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989219,0.0002744734,0.00008405196,0.00013307929,0.00043412973,0.00015241675],"domain_scores_gemma":[0.99666625,0.00079827284,0.00075061916,0.0003941259,0.00077066565,0.00062006956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026629053,0.00038895945,0.0004597503,0.0010639639,0.00035000953,0.001457281,0.0008252811,0.0017031911,0.1439676],"category_scores_gemma":[0.0050503165,0.00017789128,0.00057000294,0.0011719135,0.00058259035,0.0013096724,0.0008994285,0.0017235497,0.04015435],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077727303,0.00022318123,0.0007613942,0.0009033764,0.00005372454,0.00025061873,0.0000822887,0.00020352069,0.0065175667,0.03715644,0.54988366,0.40318713],"study_design_scores_gemma":[0.0002739336,0.00025311217,0.0016673692,0.00021875743,0.000020965981,0.00044107085,0.0000191541,0.00019729417,0.0013602339,0.0014831898,0.9940578,0.0000071031486],"about_ca_topic_score_codex":0.0025760576,"about_ca_topic_score_gemma":0.002662391,"teacher_disagreement_score":0.1439676,"about_ca_system_score_codex":0.0007978524,"about_ca_system_score_gemma":0.0031827951,"threshold_uncertainty_score":0.4816196},"labels":[],"label_agreement":null},{"id":"W205713971","doi":"10.3833/pdr.v2012i1.1646","title":"Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Diverse Perspectives in Modern Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Divestment; Prestige; Business; Cash; Shareholder; Database transaction; Order (exchange); Hard core; Advertising; Commerce; Finance; Corporate governance","score_opus":0.09439475362979195,"score_gpt":0.32693237253849217,"score_spread":0.23253761890870023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W205713971","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01979373,0.08040004,0.0014105265,0.105687514,0.0026827783,0.0002030512,0.0014698547,0.00028421864,0.78806823],"genre_scores_gemma":[0.15635204,0.059705272,0.0026506912,0.0690725,0.0025115742,0.00018063468,0.0020511718,0.00013673776,0.70733935],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984648,0.00012023423,0.000078883284,0.0001670553,0.0009962813,0.00017269551],"domain_scores_gemma":[0.9962584,0.0012200958,0.00028587802,0.00017162981,0.0017123083,0.00035171816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00182797,0.000246748,0.00054260605,0.00080511556,0.0010253374,0.0019992494,0.00052368856,0.0026750509,0.056028627],"category_scores_gemma":[0.0054553826,0.0001627471,0.00034288806,0.0012052015,0.00057234144,0.0013639365,0.00050736446,0.0013880652,0.010670451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023599004,0.0000766377,0.0028496203,0.00092416053,0.00006278174,0.00066905527,0.00024123759,0.000096784104,0.0014817913,0.057550848,0.7329201,0.20289099],"study_design_scores_gemma":[0.00003517952,0.00007712884,0.0037078008,0.00025202177,0.000031454223,0.0003595573,0.00018943219,0.000058288406,0.0003834987,0.0014980497,0.9933962,0.000011339816],"about_ca_topic_score_codex":0.022676554,"about_ca_topic_score_gemma":0.055666693,"teacher_disagreement_score":0.056028627,"about_ca_system_score_codex":0.0021202867,"about_ca_system_score_gemma":0.005974111,"threshold_uncertainty_score":0.18743443},"labels":[],"label_agreement":null},{"id":"W2285884689","doi":"10.3833/pdr.v2012i11.1832","title":"Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylphenidate; Attention deficit hyperactivity disorder; Quarter (Canadian coin); Business; Medicine; Psychiatry","score_opus":0.1161500219915705,"score_gpt":0.45813185607138196,"score_spread":0.3419818340798115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285884689","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039091716,0.05146358,0.0033998406,0.04139585,0.0086961575,0.0007575919,0.004173867,0.0029131311,0.88329095],"genre_scores_gemma":[0.019455582,0.025713349,0.00465543,0.009294651,0.0039939135,0.00022717721,0.0034699708,0.00033593996,0.93285394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99954814,0.000027669043,0.000015923748,0.000074795455,0.00028133343,0.000052079777],"domain_scores_gemma":[0.9991074,0.000111494504,0.000094359675,0.000041982046,0.0002764528,0.00036829963],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007301227,0.0009631045,0.0005006178,0.0014265834,0.00053895125,0.0015041376,0.0005006803,0.0024322395,0.35478896],"category_scores_gemma":[0.0019935796,0.00028445583,0.0005879113,0.00058495393,0.00041347847,0.0017705923,0.0007962301,0.0022070159,0.13763575],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002500426,0.00018086933,0.00026280445,0.00023038956,0.000014572403,0.00028819137,0.000023358678,0.00004959593,0.0025642407,0.0039645424,0.6998959,0.2922755],"study_design_scores_gemma":[0.00022438192,0.0002571747,0.00071736745,0.00015084934,0.000018531222,0.00050011853,0.000018722341,0.000099665594,0.00077655737,0.00068529905,0.99654204,0.000009175999],"about_ca_topic_score_codex":0.0019869723,"about_ca_topic_score_gemma":0.004608601,"teacher_disagreement_score":0.35478896,"about_ca_system_score_codex":0.0006443365,"about_ca_system_score_gemma":0.0018250237,"threshold_uncertainty_score":0.92031527},"labels":[],"label_agreement":null},{"id":"W2309079920","doi":"10.3833/pdr.v2014i9.2063","title":"Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis","year":2014,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pirfenidone; Medicine; Franchise; Idiopathic pulmonary fibrosis; Asthma; Omalizumab; Internal medicine; Business; Business administration; Lung; Immunology","score_opus":0.027396051136400222,"score_gpt":0.34447733930266766,"score_spread":0.31708128816626746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309079920","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00223454,0.62965953,0.0019852796,0.026364079,0.00960632,0.00041302678,0.0008859815,0.0007009719,0.32815024],"genre_scores_gemma":[0.031194199,0.34755898,0.005582581,0.026921263,0.0058489903,0.00036745126,0.0018608698,0.00021060501,0.58045506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995159,0.000066438675,0.0000212415,0.000072968825,0.0002555687,0.00006790166],"domain_scores_gemma":[0.9994124,0.00011642422,0.00006609215,0.00002517649,0.00017150947,0.00020826243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010159387,0.0009920998,0.0005878015,0.0010868226,0.00036272753,0.0012872748,0.000653081,0.003093891,0.098923884],"category_scores_gemma":[0.001251573,0.00024865245,0.00073152117,0.00059841096,0.00035881292,0.0012475793,0.0006108484,0.0022636477,0.06751117],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003984029,0.0002292098,0.00020515367,0.0012652973,0.000041600037,0.00064358657,0.000033383974,0.000102060694,0.005754207,0.0056879735,0.43821794,0.5474213],"study_design_scores_gemma":[0.00016797794,0.0002253866,0.0003587424,0.00028797597,0.000012901733,0.0008997417,0.000010336644,0.000030247638,0.00068976055,0.0004275905,0.99688184,0.0000074705536],"about_ca_topic_score_codex":0.0017963919,"about_ca_topic_score_gemma":0.003650979,"teacher_disagreement_score":0.098923884,"about_ca_system_score_codex":0.0006685389,"about_ca_system_score_gemma":0.0011033213,"threshold_uncertainty_score":0.3309334},"labels":[],"label_agreement":null},{"id":"W2314904138","doi":"10.3833/pdr.v2011i9.1548","title":"PerkinElmer Agrees to Acquire Caliper Life Sciences for US$600 M","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Science, Research, and Medicine","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Calipers; Portfolio; Cash; Business; Database transaction; Quarter (Canadian coin); Marketing; Computer science; Finance; Engineering; Mechanical engineering","score_opus":0.3463556383388496,"score_gpt":0.48106812351417416,"score_spread":0.13471248517532458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314904138","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010374131,0.18327774,0.15074433,0.039407033,0.014606233,0.0025972046,0.0087952,0.017811716,0.57238644],"genre_scores_gemma":[0.025908787,0.05970994,0.10086277,0.006882512,0.0026669682,0.0010815357,0.01318779,0.0021339457,0.7875657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99472284,0.0006571985,0.00024999407,0.00069231965,0.0034442935,0.00023335233],"domain_scores_gemma":[0.99458003,0.0011354527,0.00043654535,0.0004791388,0.0027572024,0.0006117196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064754426,0.0022598377,0.002271617,0.003814646,0.0011000554,0.0026498176,0.002396838,0.0034488249,0.14293908],"category_scores_gemma":[0.00682002,0.0012583793,0.0010168416,0.0019945817,0.0012901833,0.003344132,0.001232135,0.0031944,0.18689705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047952865,0.00017006727,0.00041744582,0.0015351585,0.000059357248,0.00030628932,0.000120622324,0.00024770992,0.08294902,0.010298111,0.46283987,0.4405768],"study_design_scores_gemma":[0.000052135267,0.00025601234,0.00074091885,0.000101273334,0.000043362565,0.0010024807,0.000045353783,0.0005207333,0.01990024,0.0013951276,0.9759074,0.000035029116],"about_ca_topic_score_codex":0.0015929921,"about_ca_topic_score_gemma":0.0038566147,"teacher_disagreement_score":0.14293908,"about_ca_system_score_codex":0.0012769513,"about_ca_system_score_gemma":0.0028385792,"threshold_uncertainty_score":0.47817886},"labels":[],"label_agreement":null},{"id":"W49293275","doi":"10.3833/pdr.v2012i2.1678","title":"Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics","year":2012,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Anesthesia and Neurotoxicity Research","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Xenon; General partnership; Medicine; Medical physics; Business; Engineering ethics; Medical education; Engineering; Physics; Finance; Nuclear physics","score_opus":0.18517748887070914,"score_gpt":0.40729486210594323,"score_spread":0.2221173732352341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W49293275","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074599623,0.3106348,0.013188259,0.06642397,0.010267104,0.0009565212,0.0015164211,0.0016540671,0.58789885],"genre_scores_gemma":[0.04115101,0.09075748,0.015775898,0.014424532,0.0014749055,0.00030666732,0.0020731932,0.00031911067,0.8337173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972791,0.00026892193,0.000081929466,0.0002850748,0.0016973567,0.00038769137],"domain_scores_gemma":[0.99726945,0.00039789572,0.00018430631,0.00012992449,0.00109447,0.00092399825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029013667,0.0009676749,0.00050720875,0.0015892333,0.0008175701,0.0024844466,0.0010076041,0.0035128302,0.083745696],"category_scores_gemma":[0.0034609754,0.00027491926,0.0007403853,0.0013081378,0.0008498791,0.002564354,0.0014183734,0.002813766,0.022938374],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004563009,0.00027124133,0.0009097789,0.0009225262,0.00005324159,0.00079463643,0.00023174792,0.0002454347,0.013616563,0.03634191,0.4800492,0.46610743],"study_design_scores_gemma":[0.00008304426,0.00013381407,0.0005637835,0.00012031596,0.00001961637,0.0007275178,0.00005860523,0.000104308565,0.0023628126,0.00097245234,0.9948421,0.000011657626],"about_ca_topic_score_codex":0.026225535,"about_ca_topic_score_gemma":0.042675294,"teacher_disagreement_score":0.083745696,"about_ca_system_score_codex":0.0044340137,"about_ca_system_score_gemma":0.0116731385,"threshold_uncertainty_score":0.2801572},"labels":[],"label_agreement":null},{"id":"W73664796","doi":"10.3833/pdr.v2013i11.1991","title":"Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout","year":2013,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Revenue; Stock (firearms); Business; Corporate tax; Offset (computer science); Irish; Footprint; Order (exchange); Emerging markets; Finance; Geography; Engineering; Tax avoidance; Double taxation; Mechanical engineering","score_opus":0.2162782767136228,"score_gpt":0.427603316892974,"score_spread":0.2113250401793512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W73664796","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046400603,0.3579051,0.0024831567,0.1267775,0.002904572,0.00020221247,0.002334969,0.0002428074,0.4607491],"genre_scores_gemma":[0.3387353,0.37937617,0.0065731667,0.057704408,0.002635677,0.00019161131,0.0027469757,0.00012564115,0.2119111],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996245,0.00009017874,0.000018845072,0.00004916399,0.00016586282,0.000051387546],"domain_scores_gemma":[0.9987024,0.00047161116,0.00013986809,0.000044212917,0.00052770163,0.00011421843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012803625,0.00026415574,0.0002570437,0.0010477124,0.0002984819,0.0014545788,0.00032426053,0.0009513542,0.019630417],"category_scores_gemma":[0.002578112,0.00008386374,0.0005301933,0.0012687729,0.0003240334,0.0010599984,0.0004197325,0.0010721429,0.0022424615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006755798,0.0002187108,0.0071096686,0.002053077,0.00019343157,0.00036097266,0.00021302019,0.0005393877,0.001981186,0.060485244,0.29081458,0.63535506],"study_design_scores_gemma":[0.0001438764,0.0003587939,0.014035507,0.00082366413,0.0001334849,0.00030196022,0.0002850734,0.00009200839,0.00059075456,0.002614325,0.9806002,0.000020331074],"about_ca_topic_score_codex":0.027233893,"about_ca_topic_score_gemma":0.051064793,"teacher_disagreement_score":0.027233893,"about_ca_system_score_codex":0.0018376329,"about_ca_system_score_gemma":0.0020931063,"threshold_uncertainty_score":0.06567025},"labels":[],"label_agreement":null},{"id":"W9436761","doi":"10.3833/pdr.v2011i9.1531","title":"Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Business; Nutraceutical; Portfolio; Quarter (Canadian coin); Marketing; Finance; Medicine","score_opus":0.1334269315679914,"score_gpt":0.33087790487588586,"score_spread":0.19745097330789446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W9436761","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012024104,0.20302983,0.0022400983,0.23306346,0.006268869,0.00044856136,0.0054817214,0.00042577175,0.5370175],"genre_scores_gemma":[0.17004439,0.19209348,0.0039648297,0.053962052,0.004721317,0.0003533787,0.005461279,0.00011376823,0.56928545],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988564,0.00017804753,0.00006208833,0.00010295996,0.00061699434,0.0001834527],"domain_scores_gemma":[0.99521035,0.0012932054,0.00049467105,0.00016125734,0.0022375418,0.00060291006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020471758,0.00030825136,0.00032458652,0.0012352708,0.00041791634,0.0019741312,0.00038022656,0.0016170248,0.031409185],"category_scores_gemma":[0.004791903,0.00016193152,0.00043497264,0.0011560941,0.0003454881,0.00078286155,0.00033757964,0.0015731067,0.008136394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022596713,0.00007135675,0.0016516902,0.00069890794,0.000056023946,0.00015208205,0.000039867886,0.00026179996,0.000729394,0.057114597,0.82426333,0.11473499],"study_design_scores_gemma":[0.00009742545,0.00010131369,0.005466511,0.00030901658,0.000035811165,0.00017100558,0.00003946508,0.00018321742,0.0004735681,0.0013988276,0.9917133,0.000010477409],"about_ca_topic_score_codex":0.011245494,"about_ca_topic_score_gemma":0.013880792,"teacher_disagreement_score":0.031409185,"about_ca_system_score_codex":0.0025627082,"about_ca_system_score_gemma":0.01029806,"threshold_uncertainty_score":0.10507417},"labels":[],"label_agreement":null}]}